ArticleJournal of nanobiotechnology2026
Endothelialized human umbilical cord mesenchymal stem cell-derived exosomes enhances angiogenesis and stabilizes the blood-spinal cord barrier after spinal cord injury.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Engineering MSC-Derived Small Extracellular Vesicles for Targeted Cargo Delivery to the Injured Spinal Cord.International journal of molecular sciences · 2026Review
- Recent Advances in Diversified Materials for Spinal Cord Injury Repair and Regeneration.Gels (Basel, Switzerland) · 2026Review
- Innovative Pathways in Burn Treatment: Exosomes and the New Era of Regenerative Medicine.International journal of nanomedicine · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Restoration of vascular structure and function is pivotal for neurological recovery following spinal cord injury (SCI), yet repairing the blood-spinal cord barrier (BSCB) remains a significant challenge. In this study, we demonstrate that exosomes (Exos) derived from endothelialized human umbilical cord mesenchymal stem cells (E‑UCMSCs) markedly enhance angiogenesis, improve vascular function, and promote neurological recovery. Human umbilical cord mesenchymal stem cells were induced to differentiate into endothelial‑like cells, and RNA‑sequencing revealed upregulation of genes associated with angiogenesis and vascular barrier integrity, alongside activation of relevant signaling pathways. In a co‑culture system, E‑UCMSC‑derived Exos significantly enhanced bEnd.3 cell migration and BSCB stability. To enable targeted delivery to neovasculature, Exos were engineered with RGD peptides (RGD‑E‑UCMSC‑Exos) via lentiviral modification. In vivo, these modified Exos preferentially localized to neovascular endothelial cells, promoted angiogenesis, reinforced BSCB integrity, and improved neurological outcomes in SCI mouse models. Proteomic profiling identified key angiogenic and barrier‑stabilizing factors carried by RGD‑E‑UCMSC‑Exos, including MMP2, FLT1, TIMP1, GAS6, CTHRC1, and NEO1, which likely mediate their therapeutic effects. Collectively, these findings provide novel mechanistic insights and establish a novel strong preclinical foundation for exosome‑based therapies in SCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.